Figure 3.

Patients showing a different clinical benefit from ICBs were compared between C1 and C2 groups. a, Kaplan-Meier survival curves showing OS and PFS between the C1 and C2 groups in LUAD patients from the training cohort (MSKCC) treated with anti-PD-1/PD-L1 therapy. b, Kaplan-Meier survival curves showing OS and PFS between the C1 and C2 groups in LUAD patients treated with anti-PD-1/PD-L1 therapy from the validation cohort (MSKCC). c, Kaplan-Meier survival curves of OS and PFS between the C1 and C2 groups in LUAD patients from the validation cohort (VAN ALLEN) treated with anti-PD-1/PD-L1 therapy. Abbreviations: ICB, immune checkpoint blockades; PFS, progression free survival; OS, overall survival; NR, not reached; MSKCC, Memorial Sloan Kettering Cancer Center; PD-1, programmed death receptor 1; LUAD, lung adenocarcinoma; PD-L1, programmed death receptor 1 ligand.